[go: up one dir, main page]

AU2003265853A1 - Hedgehog antagonists, methods and uses related thereto - Google Patents

Hedgehog antagonists, methods and uses related thereto

Info

Publication number
AU2003265853A1
AU2003265853A1 AU2003265853A AU2003265853A AU2003265853A1 AU 2003265853 A1 AU2003265853 A1 AU 2003265853A1 AU 2003265853 A AU2003265853 A AU 2003265853A AU 2003265853 A AU2003265853 A AU 2003265853A AU 2003265853 A1 AU2003265853 A1 AU 2003265853A1
Authority
AU
Australia
Prior art keywords
methods
hedgehog antagonists
uses related
hedgehog
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003265853A
Other versions
AU2003265853A8 (en
Inventor
Henryk K. Dudek
Irina Karavanov
Karen Kotkow
Carmen Pepicelli
Lee Rubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curis Inc
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of AU2003265853A8 publication Critical patent/AU2003265853A8/en
Publication of AU2003265853A1 publication Critical patent/AU2003265853A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003265853A 2002-08-29 2003-08-29 Hedgehog antagonists, methods and uses related thereto Abandoned AU2003265853A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40714502P 2002-08-29 2002-08-29
US60/407,145 2002-08-29
PCT/US2003/027279 WO2004020599A2 (en) 2002-08-29 2003-08-29 Hedgehog antagonists, methods and uses related thereto

Publications (2)

Publication Number Publication Date
AU2003265853A8 AU2003265853A8 (en) 2004-03-19
AU2003265853A1 true AU2003265853A1 (en) 2004-03-19

Family

ID=31978427

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003265853A Abandoned AU2003265853A1 (en) 2002-08-29 2003-08-29 Hedgehog antagonists, methods and uses related thereto

Country Status (2)

Country Link
AU (1) AU2003265853A1 (en)
WO (1) WO2004020599A2 (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709454B2 (en) * 1997-06-20 2010-05-04 New York University Methods and compositions for inhibiting tumorigenesis
US7741298B2 (en) * 1997-06-20 2010-06-22 New York University Method and compositions for inhibiting tumorigenesis
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7671200B2 (en) 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
CA2475879A1 (en) 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis of quinazolinones
NZ537076A (en) 2002-05-09 2007-06-29 Cytokinetics Inc Pyrimidinone compounds, compositions and methods
JP2005530785A (en) 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
AU2003265242A1 (en) 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003236527A1 (en) 2002-06-14 2003-12-31 Cytokinetics, Inc. Compounds, compositions, and methods
EP1537089A4 (en) 2002-07-23 2008-04-16 Cytokinetics Inc Compounds compositions and methods
AU2003277079A1 (en) 2002-09-30 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
WO2005061460A1 (en) 2003-12-08 2005-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
ES2707393T3 (en) * 2004-03-26 2019-04-03 Curis Inc RNA interference modulators of hedgehog signaling and uses thereof
WO2006101273A1 (en) * 2005-03-25 2006-09-28 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
NZ569293A (en) 2005-12-23 2011-10-28 Zealand Pharma As Modified lysine-mimetic compounds
DK2468724T3 (en) 2006-12-21 2016-02-22 Zealand Pharma As Synthesis of pyrrolidine compounds
TWI433674B (en) 2006-12-28 2014-04-11 Infinity Discovery Inc Cyclopamine analogs
WO2009086451A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2247588B1 (en) 2008-02-26 2016-04-13 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof
US20110217294A1 (en) * 2008-04-11 2011-09-08 Daniel Fults Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
AU2009241561B2 (en) 2008-04-29 2013-05-16 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
PL2364185T3 (en) 2008-11-03 2013-10-31 Lilly Co Eli Disubstituted phthalazine hedgehog pathway antagonists
JP5518887B2 (en) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー Tetrasubstituted pyridazine hedgehog pathway antagonist
EA018372B1 (en) 2008-11-17 2013-07-30 Эли Лилли Энд Компани Tetrasubstituted pyridazines hedgehog pathway antagonists
AR077014A1 (en) 2009-06-19 2011-07-27 Lilly Co Eli COMPOUND DERIVED FROM FTALAZINE 1,4-DISPOSED, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER
CA2769795C (en) 2009-08-05 2020-01-07 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
EP2471789B9 (en) 2009-08-26 2015-03-25 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
CA2771833A1 (en) 2009-08-26 2011-03-03 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
WO2011024873A1 (en) 2009-08-26 2011-03-03 武田薬品工業株式会社 Fused heterocyclic ring derivative and use thereof
US8614208B2 (en) 2009-08-26 2013-12-24 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
US8604032B2 (en) 2010-05-21 2013-12-10 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
KR20180080358A (en) 2011-01-10 2018-07-11 인피니티 파마슈티칼스, 인코포레이티드 Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CN103998442B (en) 2011-08-29 2016-09-14 无限药品股份有限公司 Heterocyclic compound and application thereof
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
DK2914296T4 (en) 2012-11-01 2022-01-03 Infinity Pharmaceuticals Inc Treatment of cancers using PI3 kinase isoform modulators
US9844541B2 (en) 2012-11-29 2017-12-19 Strasspharma, Llc Methods of modulating follicle stimulating hormone activity
WO2014144952A2 (en) 2013-03-15 2014-09-18 Peter Walter Modulators of the eif2alpha pathway
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
WO2014194254A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
ES2900806T3 (en) 2013-10-04 2022-03-18 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104906113A (en) * 2014-03-12 2015-09-16 淄博赛维医药技术有限公司 Antitumor medicine
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160986A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2016271468B2 (en) 2015-06-04 2020-01-02 Sol-Gel Technologies Ltd. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
JP6980649B2 (en) 2015-09-14 2021-12-15 インフィニティー ファーマシューティカルズ， インコーポレイテッド The solid form of the isoquinolinone derivative, the method for producing it, the composition containing it, and the method for using it.
US20170231968A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
ES2870106T3 (en) 2017-05-05 2021-10-26 Zealand Pharma As Modulators of gap junctional communication and their use for the treatment of diabetic eye disease
CN116349204A (en) 2020-10-13 2023-06-27 奋进生物医药公司 Methods of Treating Fibrosis
WO2025188802A1 (en) 2024-03-05 2025-09-12 Endeavor Biomedicines, Inc. Methods of improving lung function

Also Published As

Publication number Publication date
AU2003265853A8 (en) 2004-03-19
WO2004020599A2 (en) 2004-03-11
WO2004020599A3 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
AU2003265853A1 (en) Hedgehog antagonists, methods and uses related thereto
EP3308772B8 (en) Inhalable epinephrine
AU9684401A (en) Hedgehog antagonists, methods and uses related thereto
AU2003266321A1 (en) Tetrahydropyrimidine-2-one derivatives and their uses
AU2003262857A1 (en) Selective feature activation
AU2003273249A1 (en) Laminate structures, methods for production thereof and uses therefor
AU2003226094A1 (en) Compounds and methods
AU2003301066A1 (en) Al2o3-la2o3-y2o3-mgo ceramics, and methods of making the same
AU2003268204A1 (en) Personal area networks
AU2003207199A1 (en) Structure, method of manufacturing the same, and device using the same
AU2003270680A1 (en) Tubular structures and methods for making the same
AU2003299943A1 (en) Heterocycles and uses thereof
AU2003227976A1 (en) Meeting aid
AU2003231827A1 (en) Pseudo-tissues and uses thereof
AU2003232244A1 (en) Nanofiller, production, and use
AU2003214836A1 (en) Combined gemstone
AU2003301628A1 (en) Key unit, method for marking key top, and method for manufacturing key unit using the same
AU2003302173A1 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
AU2002952559A0 (en) New use
AU2003207181A1 (en) Microorganism-trapping agent
AU2003264722A1 (en) Methods
PL373738A1 (en) Immunosuppressant compounds, methods and uses related thereto
AU2003299336A1 (en) Diphosphines, preparation and uses thereof
AU2003300396A1 (en) Chemokine antagonists and uses thereof
AU2003275127A1 (en) P. ariasi polypeptides, p. perniciosus polypeptides and methods of use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase